However, there are several challenges
Pfizer-BioNTech’s COVID-19 vaccine, BNT-162b2, is expected to generate $30 billion in sales by 2026, with peak sales of $13.9 billion in 2021, says GlobalData.
According to data, BNT-162b2’s sales are anticipated to decline by a staggering 76% in 2022 to $3.4 billion due to competition expected from future COVID-19 vaccine approvals. Nonetheless, COVID-19 vaccines will continue to be in demand beyond 2022 if COVID-19 turns out to be a seasonal or long-term concern.
The main challenge for BNT-162b2 is the ultra-cold storage requirement of -80°C. The vaccine is likely to suffer poor uptake in countries that have limited cold-chain logistics, while Moderna’s vaccine candidate mRNA-1273, which can be stored and shipped at -20°C, could be a more attractive alternative.
We’ve reported that 70% of British small business owners feel more confident about 2021 now that the vaccine has been rolled out.